Improvement of non-paraneoplastic voltage-gated potassium channel antibody-associated limbic encephalitis without immunosuppressive therapy

Epilepsy and Behavior

Volumn 17, Issue 4, 2010, Pages 555-557

  Gast, Heidemarie ^a   Schindler, Kaspar ^a   Z'Graggen, Werner J ^a   Hess, Christian W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anticonvulsant treatment; Immunosuppression; Temporal lobe epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; FLUORODEOXYGLUCOSE F 18; OXCARBAZEPINE; VOLTAGE GATED POTASSIUM CHANNEL;

ADULT; AMNESIA; ANOSMIA; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; AUTOMATISM; CASE REPORT; CLINICAL FEATURE; CONFUSION; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG RESPONSE; ELECTROENCEPHALOGRAM; EMOTIONAL DISORDER; EPILEPTIC DISCHARGE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; MEMORY DISORDER; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; PARANEOPLASTIC NEUROPATHY; PENSIONER; POSITRON EMISSION TOMOGRAPHY; REMISSION; STEREOTYPY; TEMPORAL LOBE EPILEPSY;

ANTIBODIES; ELECTROENCEPHALOGRAPHY; FLUORODEOXYGLUCOSE F18; HUMANS; LIMBIC ENCEPHALITIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 77952240273     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.01.017     Document Type: Article

References (14)

1. Thieben M.J., Lennon V.A., Boeve B.F., Aksamit A.J., Keegan M., Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004, 62:1177-1182.
2. Vincent A., Buckley C., Schott J.M., et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004, 127:701-712.
3. Buckley C., Oger J., Clover L., et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001, 50:73-78.
4. Bien C.G., Schulze-Bonhage A., Deckert M., et al. Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology 2000, 55:1823-1828.
5. Bien C.G., Urbach H., Schramm J., et al. Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology 2007, 69:1236-1244.
6. Tan K.M., Lennon V.A., Klein C.J., Boeve B.F., Pittock S.J. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008, 70:1883-1890.
7. Fauser S., Talazko J., Wagner K., et al. FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis: correlation with clinical course and neuropsychology. Acta Neurol Scand 2005, 111:338-343.
8. McKnight K., Jiang Y., Hart Y., et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005, 65:1730-1736.
9. Jarius S., Hoffmann L., Clover L., Vincent A., Voltz R. CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. J Neurol Sci 2008, 268:74-77.
10. Majoie H.J., de Baets M., Renier W., Lang B., Vincent A. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res 2006, 71:135-141.
11. Singh G., Driever P.H., Sander J.W. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005, 128:7-17.
12. Batty N., Malouf G.G., Issa J.P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009, 280:192-200.
13. Beutler A.S., Li S., Nicol R., Walsh M.J. Carbamazepine is an inhibitor of histone deacetylases. Life Sci 2005, 76:3107-3115.
14. Knight A.K., Cunningham-Rundles C. Oxcarbazepine-induced immunoglobulin deficiency. Clin Diagn Lab Immunol 2005, 12:560-561.